IL145335A0 - Antibody and chemokine constructs and their use in the treatment of autoimmune diseases - Google Patents

Antibody and chemokine constructs and their use in the treatment of autoimmune diseases

Info

Publication number
IL145335A0
IL145335A0 IL14533500A IL14533500A IL145335A0 IL 145335 A0 IL145335 A0 IL 145335A0 IL 14533500 A IL14533500 A IL 14533500A IL 14533500 A IL14533500 A IL 14533500A IL 145335 A0 IL145335 A0 IL 145335A0
Authority
IL
Israel
Prior art keywords
antibody
chemokine
autoimmune diseases
constructs
cells
Prior art date
Application number
IL14533500A
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of IL145335A0 publication Critical patent/IL145335A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to antibody and chemokine constructs against chemokine receptor expressing cells, especially against monocytes/macrophages expressing the chemokine receptor CCR5 and CCR5<+> T cells. The invention further relates to the use of antibody and chemokine constructs for destroying cells expressing the chemokine receptor for treating autoimmune diseases and allergic diseases, especially for treating chronic inflammatory diseases of the joints. The inventive antibody and chemokine constructs facilitate the specific depletion of chemokine receptor expressing cells and thus a specific immunosuppressive therapy of autoimmune diseases.
IL14533500A 1999-03-11 2000-03-10 Antibody and chemokine constructs and their use in the treatment of autoimmune diseases IL145335A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910891 1999-03-11
PCT/EP2000/002154 WO2000053633A2 (en) 1999-03-11 2000-03-10 Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
IL145335A0 true IL145335A0 (en) 2002-06-30

Family

ID=7900625

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14533500A IL145335A0 (en) 1999-03-11 2000-03-10 Antibody and chemokine constructs and their use in the treatment of autoimmune diseases

Country Status (15)

Country Link
EP (1) EP1161456B1 (en)
JP (1) JP2002540771A (en)
CN (1) CN1345336A (en)
AT (1) ATE286074T1 (en)
AU (1) AU4104700A (en)
CA (1) CA2366713A1 (en)
CZ (1) CZ20013270A3 (en)
DE (1) DE50009113D1 (en)
ES (1) ES2233359T3 (en)
HU (1) HUP0200484A2 (en)
IL (1) IL145335A0 (en)
NO (1) NO316916B1 (en)
SK (1) SK12782001A3 (en)
TR (1) TR200102779T2 (en)
WO (1) WO2000053633A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
PL366062A1 (en) * 2000-09-08 2005-01-24 Micromet Ag Antibody and/or chemokine constructs and their use in immunological disorders
EP1456241B1 (en) * 2001-12-21 2005-03-16 Micromet AG Mono-and dual anti-cd4-rantes chemokine/cytokine constructs
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
KR101105610B1 (en) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0717512A2 (en) 2006-09-29 2013-11-19 Hoffmann La Roche CCR5 ANTIBODIES AND USES OF THE SAME
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
PT2647707T (en) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP3130606B1 (en) 2014-04-07 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Immunoactivating bispecific antibodies
CA2947157A1 (en) * 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
ZA985542B (en) * 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
JP4454152B2 (en) * 1998-07-22 2010-04-21 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド Methods and compositions for treating secondary tissue damage and other inflammatory conditions and diseases

Also Published As

Publication number Publication date
NO316916B1 (en) 2004-06-21
EP1161456B1 (en) 2004-12-29
HUP0200484A2 (en) 2002-06-29
CN1345336A (en) 2002-04-17
AU4104700A (en) 2000-09-28
SK12782001A3 (en) 2002-03-05
TR200102779T2 (en) 2002-03-21
EP1161456A2 (en) 2001-12-12
NO20014346D0 (en) 2001-09-06
CA2366713A1 (en) 2000-09-14
NO20014346L (en) 2001-09-27
CZ20013270A3 (en) 2002-02-13
JP2002540771A (en) 2002-12-03
ES2233359T3 (en) 2005-06-16
ATE286074T1 (en) 2005-01-15
DE50009113D1 (en) 2005-02-03
WO2000053633A3 (en) 2000-11-16
WO2000053633A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
IL145335A0 (en) Antibody and chemokine constructs and their use in the treatment of autoimmune diseases
AU5811001A (en) Cxcr4 antagonist treatment of hematopoietic cells
NZ593428A (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU4455896A (en) A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
EP2283866A3 (en) Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
AU2001263114A1 (en) Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
FR14C0051I2 (en) DIALKYLFUMARATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP1097709A3 (en) Use of corticotropin releasing factor antagonists for treating syndrome X
DE60135498D1 (en) Production of Whole Antibodies in Prokaryotic Cells
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
HK1068885A1 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases n--
AU2000233235A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
WO2000006086A3 (en) Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
PT1331944E (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28
WO2004032850A3 (en) Uses of human zven antagonists
WO2005009366A3 (en) Restoring vascular function
GB0102145D0 (en) Substances
ES2013321A6 (en) Monoclonal antibodies to Pseudomonas aeruginosaflagella
HK1029099A1 (en) 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
AP2000001950A0 (en) Paroxetine maleate.